+ : 12.8%) and Isolex300/Isolex50 (n = 2; TCD: 3.8 log; yield CD34 + : 43.2%). Furthermore, we have established and tested a new simultaneous ؉/؊ selection method by using CD34-specific releasing agent PR34؉ in the Isolex300i. With this method we have obtained a mean total yield-corrected TCD of 4.7 log (n = 4; range: 4.1-6.0 log) with high CD34 + cell yield (mean: 69.8%) and CD34 + cell purity (mean: 92.8%). Since this new simultaneous ؉/؊ purging procedure is safe, applicable within a closed system (GMP-like) and most effective, we recommend it for further testing in a clinical setting.
within a closed system (GMP-like) and most effective, we recommend it for further testing in a clinical setting. Keywords: autotransplantation; peripheral hematopoietic stem cells; immunomagnetic double selection; CD34 selection; tumor cell purging Phase III studies have shown a benefit of high-dose chemotherapy (HDC) with stem cell support compared with conventional therapy in malignant diseases such as acute myelogenous leukemia (AML), 1 Hodgkins disease, 2 lymphoma, 3 ,4 myeloma, 5 and breast cancer. 6 Peripheral blood progenitor cells (PBPC) have nearly replaced bone marrow (BM) as a source of autologous hematopoietic stem cells used for hematopoietic rescue after HDC. In contrast to bone marrow harvest the collection of PBPC using a cell separator abrogates any need of general anesthesia. Furthermore, hematopoietic recovery is faster [7] [8] [9] contributing to feasibility and lower lethality of HDC protocols. Additionally, tumor cell (TC) contamination is lower in PBPC than in BM samples. 10 In the last years solid tumors such as breast cancer became an important area for studying PBPC transplantation following HDC. 11 The high prognostic value of bone marrow micrometastases 12 and the mobilization of these cells into the peripheral blood following priming for PBPC collection are well known. [13] [14] [15] Diel et al 12 showed that at the time of surgery, in 31% of even the node-negative patients with breast cancer, bone marrow micrometastases can be found and that the BM status is an independent prognostic factor with a prognostic value higher than the nodal status.
Retrospective studies indicate that TC contamination of stem cell autografts may be an important factor for the prognosis of BC, Hodgkin's disease, lymphoma and AML patients after HDC and retransfusion. [16] [17] [18] [19] Direct evidence for a relapse caused by contaminating TC was presented by gene-marking studies in leukemia and neuroblastoma. [20] [21] [22] Although their negative influence on the clinical outcome after stem cell retransfusion is still not proven by randomized prospective phase III studies, the reduction of residual tumor cells is a main objective of leukapheresis product (LP) processing. A large number of depletion methods has been developed. 23 The immunomagnetic CD34 ϩ cell enrichment (selection) is a widely applied and effective purging procedure.
14, 24 An additional purging Here, we have studied double-purging methods consisting of combinations of several immunomagnetic positive and negative selection systems, ie positive selection of CD34 positive hematopoietic stem cells (ϩ selection) using Isolex50 or Isolex300SA magnetic cell separators and negative tumor cell depletion (Ϫ selection) using MACS, MaxSep, or Isolex50. Using peripheral blood mononuclear cells artificially contaminated with tumor cells we measured tumor cell depletion (TCD) and yield of CD34-positive hematopoietic stem cells (CD34 ϩ cells) after the first selection step and double selection. Additional tumor cell depletion (⌬TCD), yield-corrected TCD, and yield-corrected ⌬TCD of double selection procedures were calculated. Furthermore, we have established and tested a new simultaneous ϩ/Ϫ selection method by using CD34-specific releasing agent PR34ϩ in the Isolex300i.
Materials and methods

Peripheral blood mononuclear cells
Fresh peripheral blood mononuclear cells (PBMNC) were collected after mobilization of hematopoietic stem cells with chemotherapy and filgrastim (Amgen, Munich, Germany) from patients before HDC, or in the case of one Isolex50/MaxSep and two MaxSep/Isolex50 selections after filgrastim mobilization from healthy donors for allogeneic transplantation. We have used an automated continuous flow cell separator (COBE Spectra Apheresis System, Heimstetten, Germany; Baxter CS-3000Plus, Baxter, Munich, Germany). For sequential double selection 1 ϫ 10 9 MNC were used with the exception of two double selections (Isolex300SA/Isolex50) where 1 ϫ 10 10 MNC were taken for the experiments. For simultaneous double selection 1-5 ϫ 10 10 MNC were taken for experiments (clinical scale). According to our ethical board requirements, written informed consent was obtained from every patient or donor for using surplus PBMNC for experiments.
Tumor cell fluorescence labeling and detection
Adherent tumor cells from breast cancer tumor cell lines HTB 19, 22 , and 131 (American Type Culture Collection, Rockville, MD, USA) were used. Cultured tumor cells were detached using EDTA and washed twice with working buffer (see below). In every case tumor cell viability determined by trypan blue dye exclusion test was greater than 90%.
FITC labeling: Tumor cells were labeled according to a method described by Butcher et al. 27 Briefly, tumor cells were resuspended to a final cell concentration of 5 ϫ 10 7 cells/ml and incubated (30 min, 37°C) in working buffer containing fluorescein isothiocyanate (FITC) at a concentration of 100 g/ml. After incubation, the cell suspension was underlayed with fetal calf serum (FCS) and centrifuged (400 g, 30 min, 4°C, w/o brake). Supernatant was eliminated and cell pellet washed twice with FCS. Cells were resuspended in a small volume of working buffer supplemented with 0.5% human immunglobulin (Gammagard SD; Baxter). FITC labeled tumor cells were detected using fluorescence microscopy. Tumor cell labeling rate was greater than 99.5%.
Hoechst 33342 labeling:
After nine sequential double selection experiments, our method for tumor cell labeling was changed to nuclear fluorescence dye Hoechst 33342 according to the method of Reynolds et al. 28 Briefly, tumor cells were resuspended to a final cell concentration of 5 ϫ 10 7 cells/ml and incubated (30 min, 37°C) in working buffer containing nuclear fluorescence dye Hoechst 33342 (Sigma-Aldrich, Deisenhofen, Germany) at a concentration of 2 g/ml. After incubation, the cell suspension was washed three times using working buffer. Tumor cells were resuspended in a small volume of working buffer supplemented with human immunglobulin. Hoechst 33342 labeled tumor cells were detected using fluorescence microscopy. Tumor cell labeling rate was greater than 99.5%.
Immuncytochemical staining:
In all simultaneous ϩ/Ϫ selection experiments we performed immuncytochemical staining for tumor cell detection. Aliquots of the cell suspensions were investigated before and after the purging procedure for contaminating tumor cells by microscopy after cytospin preparation and immuncytochemical staining (Epimet-Epithelian Cell Detection Kit; Micromet, Munich, Germany). Cells were centrifuged on to glass slides at a density of 2000 cells per mm 2 . The detection method is based on the reactivity of the murine mAb A45-B/B3 linked to alkaline phosphatase with the cell cytoskeleton after membrane permeabilization. This mAb has no cross-reactivity with the MoAbs used for selection. Cytokeratin-positive cells show a new fuchsin red color after staining. We stained 1 ϫ 10 7 cells from the LP and the purged fraction. The sensitivity of the method was in excess of 1 TC per 1 ϫ 10 7 cells.
Tumor cell contamination of PBMNC in the sequential selection experiments
The HTB cell lines were tested for absence of CD34 antigen expression by flow cytometry (FACScan; Becton Dickinson, Heidelberg, Germany). Before exposure to immunomagnetic separation PBMNC were exogenously contaminated with fluorescence labeled tumor cells (see below). For the sequential selection experiments tumor cell contamination rate ranged from 0.32% to 16% (n = 20, median: 5.2%). MNC from the cell suspension at the beginning (start fraction), after the first selection step, or after double selection were washed once with flow cytometry buffer (phosphate buffered saline (PBS), 0.5% bovine serum albumin (BSA) and 0.01% sodium azide) and centrifuged (400 g, 5 min, 4°C 
Characterization and evaluation of purging efficiency
The efficiency of immunomagnetic double selection was evaluated by applying the definitions shown in this section. Purity and yield of CD34 ϩ hematopoietic cells during selection procedure were characterized by the following equations:
Tumor cell contamination rate in start fraction and remaining tumor cells after one and both selection steps were determined by fluorescence microscopy. Tumor cell depletion (TCD) (log) of the first selection step and double selection was characterized by the following equation: Additional tumor cell depletion (⌬TCD) in the sequential selection procedures was calculated as:
For evaluating purging efficiency of one or both selection steps TCD was corrected for non-specific loss of CD34 ϩ cells, yielding in a non-specific, not directly purging-related tumor cell loss effect. A measure of non-specific cell loss during both selection steps is loss of CD34 ϩ cells. This yield corrected TCD (corr TCD) was defined as: 
Tumor cell determination was not biased by co-labeling with FITC of MNC mentioned above because co-labeled MNC were easily distinguishable from bright tumor cell labeling.
Sequential selection procedures
Sequential double selection experiments consisted of the combination of one of the positive and one of the negative selection procedures described in this section. Depending on selection sequence, negative selection procedures as first or second selection step differed slightly as described below.
Working buffer was the same in every selection procedure. It consisted of Dulbecco's phosphate buffered saline, 1% human serum albumin, and 5% ACD-A. Before selection fresh PBMNC were washed twice in working buffer to diminish the number of platelets. The pellet was resuspended and cells were contaminated with fluorescence labeled tumor cells.
Isolex50 for positive selection:
Cell suspension (1-5 ϫ 10 7 MNC/ml) was incubated for 15 min at room temperature (RT) in working buffer supplemented with 0.5% human immunglobulin (Gammagard SD; Baxter). Subsequently, cells were sensitized with mouse anti-human CD34 antibody 9C5 (Baxter) for 30 min (RT; slow end-over-end rotation). Sensitized cells were washed three times with working buffer supplemented with 0.5% human immunglobulin to remove unbound antibodies. Washed paramagnetic microbeads coated with sheep anti-mouse IgG1 (Fc) antibodies (Dynabeads M-450; Dynal, Oslo, Norway) and sensitized MNC were mixed in the disposable Isolex 50 chamber (Baxter) at a ratio of 1:2, and incubated for 30 min (4°C; slow end-over-end rotation) to allow rosette formation. Beads and rosetted target cells were then captured by exposure to the magnet of the Isolex 50 magnetic cell separator (Baxter) and washed three times with working buffer. Unbound cells were removed by gravity flow. Rosetted cells were released from the beads by incubation (4°C; slow end-over-end rotation) with ChymoCell-T (Baxter) or PR34ϩ releasing agent (Baxter) for 15 or 30 min, respectively. In ϩ/Ϫ selection CD34 ϩ enriched cell suspension was used for second (negative) selection, in Ϫ/ϩ selection it was analyzed for tumor cell contamination and CD34 ϩ cell content.
Isolex300SA for positive selection: Semi-automatic separation procedure by Isolex300SA (Baxter) was similar to manual procedure of Isolex50. Differences are described briefly in this section. Cell suspension was incubated for 15 min (RT; 1 ϫ 10 8 MNC/ml) with working buffer supplemented with human immunglobulin. All incubation steps MNC/ml) with murine monoclonal antibodies (mAb) 520C9, 260F9, and 317G5 (Baxter), which are breast cancer targetted. Antibody concentration was 10 g/ml. After two washing cycles, sensitized cell suspension was incubated with 20 l goat anti-mouse coated paramagnetic microcolloidal particles (GAM-IgG beads, Miltenyi) per 1 ϫ 10 7 MNC for 30 min (4°C; 1 ϫ 10 8 MNC/ml). After washing twice cell suspension was magnetically separated on CS column of MACS system and double selected cell fraction eluted twice with 500 l working buffer.
MaxSep for negative selection (Ϫ/ϩ selection sequence):
For negative selection in Ϫ/ϩ selection sequence cells resuspended with working buffer supplemented with 0.5% human immunglobulin were incubated with murine mAbs 520C9, 260F9, and 317G5 in an antibody concentration of 10 g/ml for 30 min (4°C; 5 ϫ 10 7 MNC/ml). After washing three times, cells were resuspended with working buffer supplemented with 0.5% human immunglobulin and incubated for 30 min (4°C; 5 ϫ 10 7 MNC/ml; slow end-over-end rotation) with Dynabeads M-450 in a ratio of 0.75 beads/MNC to allow tumorcell bead rosetting. Working buffer was added to a final volume of 150 ml and cells were transferred into a Lifecell Tissue Culture Flask (1000 ml, Baxter). Cell suspension was exposed for 5 min to the cooled primary magnet of the MaxSep (Baxter) magnetic cell separator (exposition angle: 0°). Primary magnet was inclined to an separation angle of 15°and negative selected cell fraction was collected at a flow rate of 5 ml/min. This cell fraction was used for second (positive) selection.
MaxSep for negative selection (ϩ/Ϫ selection sequence): Differences in selection procedure depending on selection sequence are due to differences of cell quantity and are described in this section. Briefly, CD34 enriched cells (1-5 ϫ 10 6 MNC/ml) were incubated for 30 min with murine mAbs 520C9, 260F9, and 317G5 in an antibody concentration of 10 g/ml. Washed and sensitized cells (1-5 ϫ 10 6 MNC/ml) were incubated for 30 min with Dynabeads M-450 in a ratio of two beads/MNC. After adding working buffer to a final volume of 50 ml, cells were transferred into a Lifecell Tissue Culture Flask (300 ml, Baxter). Separation procedure with MaxSep magnetic cell separator was identical to the Ϫ/ϩ selection sequence. Flow rate was reduced to 1 ml/min.
Isolex50 for negative selection (ϩ/Ϫ selection sequence):
In the ϩ/Ϫ selection sequence using Isolex300SA/Isolex50 for second (negative) selection a modified Isolex50 separation chamber with an attached secondary chamber was used, which was loaded in Isolex300SA separator by two adapters. CD34-enriched cells were washed three times and resuspended in 9 ml working buffer. Murine mAbs 520C9, 260F9, and 317G5 (20 l
Simultaneous ϩ/Ϫ selection
After storage of the collected cells of LP (1-5 ϫ 10 10 MNC from surplus material, clinical scale; culture medium/HSA 1:1, 4°C, for max 48 h) from patients without diagnosis of epithelial tumors (informed consent of the patients was obligatory) contamination of cells with the human breast cancer cell lines HTB 22, HTB 131 and HTB 19 at tumor cell concentrations of 0.5% and 5% was performed. Immunomagnetic CD34 ϩ cell enrichment (Isolex 300i, standard set and software, Baxter) was performed (temperature Ͻ25°C) as described by the manufacturer with the following modifications. During the procedure, following the transfer of the specific competitive stem cell releasing agent (PR34ϩ; Baxter) to the separation column, we added mAbs (520C9, 260F9, and 317G5) as above against breast cancer glycoproteins (42 kDa, 55 kDa, 200 kDa, Baxter) preincubated with immunobeads (Dynabeads M-450, precoated with rat anti-mouse) for additional negative selection of tumor cells. To avoid cell clumping during the procedure the separation column was prefilled with 2500 U Pulmozyme (Roche, Grenzach, Germany) ϩ 1.0 mm Mg 2ϩ (Cl Ϫ ) 2 per 1 ϫ 10 10 cells.
Results
In a first set of experiments we have tested different system combinations for sequential selection of cells. In these experiments only one separation cycle for ϩ and Ϫ separation was used to avoid further cell loss.
Correlation of yield (MNC) and yield (CD34 ϩ ) during negative selection
Data of 12 double selection experiments were evaluated for yield of MNC and CD34 ϩ cells during the negative selection step to show that cell loss during negative selection was non-specific. This evaluation was necessary to show the usefulness of MNC yields for yield correction of TCD in experiments where the yield of CD34 ϩ cells could not be determined by flow cytometry. The relationship of yield (MNC) and yield (CD34 ϩ ) was analyzed using a standard linear regression model. There was a strong correlation (r = 0.95) of yield (MNC) with yield (CD34 ϩ ) during negative selection (Figure 1) .
Purging efficiency of different sequential double selection procedures
Purging efficiencies of double selection procedures were evaluated by means of tumor cell depletion (TCD) of each single selection step and of double selection, additional tumor cell depletion (⌬TCD), and yield (CD34 ϩ ). Comparing mean values of TCD of the double selection procedures studied, only trends could be shown in favor of specific selection systems used (Figure 2) . However, range of TCD of these double selections were different, favoring combinations of the Isolex system with MaxSep or Isolex (Isolex50/MaxSep (range: 3.1-6.1 log; mean: 4.2 log (mean CD34 ϩ cell content at start: 4.4%)), MaxSep/Isolex50 (range: 1.9-5.8 log; mean: 3.2 log (mean CD34 ϩ cell content at start: 1.3%)), Isolex300SA/Isolex50 (range: 3.2-4.3 log; mean: 3.8 log (mean CD34 ϩ cell content at start: 0.33%))). Double selection by Isolex50/MACS showed lower TCD (range: 3.2-3.5 log; mean: 3.4 log (mean CD34 ϩ cell content at start: 7.8%)). Calculating mean additional tumor cell depletion achieved by second selection step (⌬TCD) there were only small differences between the methods applied ( Figure 3) . Maximum ⌬TCD was found for double selections using combinations of Isolex and MaxSep system with ranges of 0.9 to 3.1 log (mean: 1.7 log) (Isolex50/MaxSep) and 0.8 to 4.3 log (mean: 2.0 log) (MaxSep/Isolex50).
Loss of CD34 ϩ cells during purging procedures results in tumor cell loss not directly purging-related and diminishes clinical applicability. For these reasons yields of CD34 
2%). In experiments where direct determinations of CD34
ϩ cell loss during positive and negative selection were possible, the cause of sometimes high loss during double selection could not be specifically attributed to one or both selection principles. Yield-correction of data for mean TCD and mean ⌬TCD (Figures 2 and 3) indicated that including CD34 ϩ cell loss during double selection TCD had to be reduced for 0.8 log (Isolex50/MACS), 1 log (Isolex50/MaxSep), and 1 log (MaxSep/Isolex50). The difference between mean TCD and mean corr TCD was low for Isolex300SA/Isolex50 (0.5 log). These differences between mean TCD and mean corr TCD were caused likewise by CD34 ϩ cell loss during first and second selection step (Isolex50/MACS (0.3*/0.5* log), Isolex50/MaxSep (0.3*/0.7* log), MaxSep/Isolex50 (0.4/0.6 log), Isolex300SA/Isolex50 (0.3/0.2 log)).
In two pairs of double selections where combinations of Isolex50/MaxSep and MaxSep/Isolex50 were studied at the same time with the same start fractions Isolex50/MaxSep showed better results for mean yield (CD34 ϩ ) than the reverse selection sequence ( Figure 5 ). Mean yield-corrected ᭝TCD was higher in ϩ/Ϫ selection-sequence (0.7 log) than in Ϫ/ϩ selection sequence (0.4 log).
Comparison of relative tumor cell contamination rates during double selection procedures of both selection sequences showed differences between the ϩ/Ϫ and Ϫ/ϩ selection sequences ( Figure 6 ). Whereas all double selections in the ϩ/Ϫ selection sequence showed the expected reduction in tumor cell contamination rate during the complete selection procedure, ie constant or only slightly diminished contamination rate after positive selection and marked reduction of contamination rate after negative selection, in Ϫ/ϩ selection sequence unexpected changes in contamination rate could be demonstrated. Here, contamination rate was reduced during the first (negative) selection step. After the following second (positive) selection step a relative tumor cell enrichment was detectable, increasing mean contamination rate from 0.66 Ϯ 0.32% to 9.6 Ϯ 13.9%. This tumor cell enrichment was variable in extent resulting in a high standard deviation, but was detectable in all but one Ϫ/ϩ double selection experiments.
Characterization of single selection steps within the sequential double selection procedures
We have evaluated purging efficiencies of isolated immunomagnetic positive or negative selections, depending on their position in double selection sequence. TCD, yield (CD34 ϩ ), and corr TCD were determined. Tumor cell depletions by both selection principles showed a larger variability when done as second selection step, compared to TCD of these selections first (data not shown). Positive selection (Isolex50 or Isolex300SA) as first selection step was more efficient in tumor cell removal (2.4 Ϯ 0.4 log) than as second selection (2.0 Ϯ 1.1 log). For negative selection (MaxSep) the inverse situation was seen (first step: 1.2 Ϯ 0.2 log; second step: 1.7 Ϯ 1.0 log).
Purging efficiency of the simultaneous cell selection procedure
Surplus cells of leukapheresis products of four donors with a diagnosis other than epithelial tumor and morphologically normal bone marrow were contaminated with cells from three different human breast cancer cell lines. In the following experimental simultaneous ϩ/Ϫ selection runs the mean yield of CD34 ϩ cells was 69.8% and the mean CD34 ϩ cell purity was 92.8%. The yield corrected tumor cell depletion (corr TCD) ranged between 4.1-6.0 log ( Table 1) . This was considerably better than results of two clinical scale sequential +/− selection tests (Table 2) .
Discussion
The clinical relevance of tumor cell purging from hematopoietic stem cell autografts prior to reinfusion after HD therapy is still an open question. Randomized studies dealing with this problem do not exist so far. However, genemarking studies, [20] [21] [22] [23] case reports and the well known fact that even in remission occult tumor cells can be detected in bone marrow and peripheral blood 15, 30 argue in favor of the application of purging procedures. Thus, different purging methods have been developed. 23, 24, 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] In this study, we have evaluated different sequential and simultaneous double-purging methods consisting of combinations of several positive and negative immunomagnetic selection systems. Purging efficiencies were characterized by tumor cell depletion (TCD) and in the case of sequential procedures additional TCD (⌬TCD) achieved by double selection or second selection step, respectively. Non-specific loss of CD34 ϩ cells was taken into account, and yieldcorrected TCD or ⌬TCD (corr TCD/⌬TCD) were calcu- Tumor cell contamination rate during double selection procedures. Mean relative tumor cell contamination rate (%) is shown for cell fraction at start, after first selection step, and after double selection. ϩ/Ϫ Selection sequence (n = 13) and Ϫ/ϩ selection sequence (n = 7) are compared. Although effective ⌬TCD values for tumor cell purging in order of magnitude of 1 log could be achieved, all sequential procedures tested revealed problems with CD34 ϩ cell yield to such an extent that they cannot be recommended for clinical application (see . This is particularly the case for patients with poor mobilization of CD34 ϩ cells. Furthermore, we have observed unexpected relative tumor cell enrichment when ϩ selection of
CD34
ϩ cells was the second step in the sequence. A possible explanation for this could be antibody binding to tumor cells and subsequent inefficient binding of immunomagnetic beads to these antibody-labeled tumor cells. These tumor cells, which are not labeled with beads, may become bound by immunomagnetic beads during incubation for the second (positive) selection step and are possibly concomitantly enriched along with regular antibody and beadmarked CD34 ϩ cells. In contrast, with the newly developed simultaneous double-purging method we have obtained a mean total corr TCD of 4.7 log (n = 4; range: 4.1-6.0 log) with high CD34 ϩ cell yield (mean: 69.0%) and CD34 ϩ cell purity (mean: 92.8%). Yield and purity are comparable with previous results using similar devices for CD34 ϩ cell selection only. 24, 29, 36 Some caution is needed in interpreting these results, since differences in tumor cell contamination rate could influence purging efficacy (see Table 1 ). However, first clinical data strongly support that the new simultaneous purging procedure with low contamination rates in the clinical situation has the efficacy estimated by our experimental design (Mohr et al, manuscript in preparation). Since this new simultaneous ϩ/Ϫ purging procedure is most effective, safe, and can be performed within a closed system (GMP-like), we recommend it for further testing in a clinical setting.
Comparing the number of reagents necessary for sequential double selection procedure ϩ/Ϫ selection sequence is more cost-effective than Ϫ/ϩ selection sequence, because the quantity of antibodies and immunomagnetic beads needed for the second (negative) selection step is diminished by cell reduction due to enrichment of CD34 ϩ hematopoietic stem cells during the first (positive) selection step. However, there is a considerably lower need for reagents using the simultaneous procedure which increases costs only by approximately 20% when compared with CD34 ϩ cell selection only.
Today mainly three different purging methods are used clinically, which are still intensively tested for methodological improvement and clinical relevance. Apart from positive stem cell selection (eg immunomagnetically with anti-CD34 antibodies) there are negative selection techniques in which tumor cells are eliminated either immunologically by anti-tumor antibodies or chemically-pharmacologically by toxin or drug exposure. 16, 17, 31, 32, 38, [39] [40] [41] [42] Choosing a positive stem cell selection system offers multiple advantages. CD34 ϩ hematopoietic cells can be enriched to Ͼ90% (our data) before reinfusion into the patient. This means less volume, less freezing medium and therefore less potential toxicity for the patient. CD34 ϩ cells of LP show a full capability of restoring hematopoiesis when administered following HD therapy 42 and identical reconstitution of hematopoiesis as with unseparated leukapheresis. 43 However, immunomagnetic CD34
ϩ cell selection with dependence on purity can decrease tumor cell numbers by only 1.9-2.75 log as reported before. 14, 24 On the other hand, negative selection techniques bear the risk of purging damage of hematopoietic stem cells. 38, 44 Some studies show depletion of normal hematopoietic cells, delay in engraftment and an increasing risk of myelosuppressive complications. This can be due to simultaneous toxic effects by chemotherapeutics and/or immunotoxins on hematopoietic precursor cells. In addition, the efficiency of chemically purging breast cancer cells in vitro with 4-hydroperoxycyclophosphamide (4-HC) is 1-2 log depletion 35 similar to the procedure with ether lipids and subsequent cryopreservation 34 and has only low efficacy. Removal of 1-4 log of tumor cells with one purging cycle was seen when using a cocktail of three different anti-tumor antibodies. 40 Anderson et al 35 combined immunomagnetic purging with 4-HC and eliminated up to 5 logs of clonogenic breast cancer cells but with a reduced recovery (Ͻ50%) of colony-forming units granulocyte/macrophage.
These data and the results of the new simultaneous double purging technique presented here recommend the latter technique for clinical testing.
